ANTIBIOTICE S.A. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.935 RON | +1.31% |
|
+3.20% | +38.71% |
| Sales 2021 | 379M 81.23M | Sales 2022 | 497M 107M | Capitalization | 380M 81.47M |
|---|---|---|---|---|---|
| Net income 2021 | 29M 6.22M | Net income 2022 | 38M 8.15M | EV / Sales 2021 | 1.45 x |
| Net Debt 2021 | 143M 30.59M | Net Debt 2022 | 79.25M 16.99M | EV / Sales 2022 | 0.92 x |
| P/E ratio 2021 |
13.6
x | P/E ratio 2022 |
9.87
x | Employees | 1,350 |
| Yield 2021 |
0.53% | Yield 2022 |
1.4% | Free-Float | 17.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.31% | ||
| 1 week | +3.20% | ||
| Current month | +11.85% | ||
| 1 month | +14.16% | ||
| 3 months | +17.63% | ||
| 6 months | +61.25% | ||
| Current year | +38.71% |
1 week
1.82
1.94
1 month
1.672.00
Current year
1.362.01
1 year
0.552.01
3 years
0.482.01
5 years
0.412.01
10 years
0.412.01
| Managers | Title | Age | Since |
|---|---|---|---|
Ioan Nani
CEO | Chief Executive Officer | 64 | 86-12-31 |
| Director of Finance/CFO | 56 | 90-12-31 | |
Cornelia Moraru
CTO | Chief Tech/Sci/R&D Officer | 58 | 03-01-04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ioan Nani
CEO | Chief Executive Officer | 64 | 86-12-31 |
Ionel Damian
BRD | Director/Board Member | 52 | 21-04-20 |
Mihai Trifu
BRD | Director/Board Member | 41 | 21-08-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 1.935 | +1.31% | 167,778 |
| 24-04-18 | 1.91 | +2.96% | 227,615 |
| 24-04-17 | 1.855 | 0.00% | 74,993 |
| 24-04-16 | 1.855 | -1.33% | 140,321 |
| 24-04-15 | 1.88 | +0.27% | 35,531 |
End-of-day quote Bucharest S.E., April 18, 2024
More quotes
Antibiotice SA is a Romania-based company primarily active in the pharmaceutical industry. The Company manufactures drugs in five pharmaceutical forms: powder for injectable solutions and suspensions, capsules, tablets, suppositories and preparations. The Company's products are designed to treat a range of diseases, including infectious, dermatology, cardiovascular, digestive and musculoskeletal system related. The Company operates eight certified production lines. Its portfolio includes products for human and veterinary use, pharmaceutical ingredients and biological fertilizers. Additionally, the Company is engaged in the research and development activities.
Sector
Pharmaceuticals
Calendar
2024-09-22
- Ex-dividend day for final dividend
| 1st Jan change | Capi. | |
|---|---|---|
| +38.71% | 278M | |
| +24.60% | 654B | |
| +24.08% | 552B | |
| -5.63% | 356B | |
| +15.37% | 319B | |
| +7.38% | 295B | |
| +3.26% | 211B | |
| +0.78% | 206B | |
| -9.69% | 147B | |
| -6.63% | 144B |
- Stock Market
- Equities
- ATB Stock
